- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential submission for U.S. Accelerated Approval in H1 2026 - - Registrational Expansion Cohort of DELIVER Trial of DYNE-251 in DMD fully enrolled to support potential submission for U.S. Accelerated Approval in early 2026 - WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIR ...

Core Insights - Verano Holdings Corp. reported its financial results for Q1 2025, showing a decrease in revenues and gross profit compared to previous quarters, primarily due to increased promotional activity and price compression in key markets [1][5][6] Financial Performance - Revenues for Q1 2025 were $210 million, down 5% year-over-year from $221 million in Q1 2024 and down 4% from $218 million in Q4 2024 [5][8] - Gross profit for Q1 2025 was $100 million, representing 47% of revenue, a decline from 51% in Q1 2024 and 49% in Q4 2024 [6][8] - The company reported a net loss of $12 million, or 5% of revenue, compared to a net loss of $5 million, or 2% of revenue, in Q1 2024 [10][8] - Adjusted EBITDA for Q1 2025 was $54 million, or 26% of revenue, down from $66 million, or 30% of revenue, in Q1 2024 [10][31] Operational Highlights - The company expanded its retail footprint by opening new dispensaries, bringing its total to 81 in Florida and 155 across 13 states [15] - Verano launched new products in response to market demand, including innovative vapes and pre-roll joints [15] - The company secured an additional $12 million in financing by leveraging its owned CPG real estate in Nevada and Arizona [15] Management Commentary - The CEO expressed satisfaction with the company's progress in executing strategic priorities, emphasizing innovation, automation, and operational efficiencies [4]

Core Insights - Teradyne, Inc. is experiencing significant market challenges due to ongoing disruptions in international trade linked to U.S. tariff policies [1] - The outlook for Q2 '25 indicates growth and margin expectations falling short, primarily due to customers delaying deliveries [1] Company Summary - Teradyne's current market position is adversely affected by external trade policies, which are creating headwinds for its operations [1] - The company's anticipated performance for the upcoming quarter suggests a decline in both growth and profit margins, raising concerns among investors [1]

Core Viewpoint - Alvotech anticipates that potential U.S. tariffs on imported pharmaceuticals will have minimal impact on its product revenues in 2025, estimating the effect of a 10% tariff to be less than 1% of expected total product revenues [1][2]. Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space by providing high-quality, cost-effective products [3]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [3]. - Alvotech has established strategic commercial partnerships across multiple regions, including the U.S., Europe, Japan, and parts of South America, Africa, and the Middle East [3]. Tariff Impact Analysis - The company manufactures its biosimilars in Iceland, which currently faces a minimum tariff of 10% on goods imported to the U.S. [1][2]. - According to the company's estimates, the impact of a 10% tariff on U.S. sales in the second half of the year would be less than 1% of expected product revenues in 2025, with costs not borne by Alvotech due to contractual terms [2]. - Looking beyond 2025, the anticipated impact of tariffs is expected to remain a low single-digit percentage of total product revenues, considering future product launches and increased sales [2].

Q1 2025 Financial Results May 6, 2025 (Nasdaq: SEAT) Agenda Business Highlights & Updates Stan Chia, Chief Executive Officer 2 Financial Results & Outlook Lawrence Fey, Chief Financial Officer Important Disclaimers Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "can," "continue," "could," "design," "estimate," "expect," "f ...

1Q 2025 Earnings Conference Call May 5, 2025 Forward-Looking Statements Statements made during this presentation that set forth expectations, predictions, projections or are about future events are based on facts and situations that are known to us as of May 5, 2025. We believe that our expectations and assumptions are reasonable. Actual results may differ materially, due to risks and uncertainties, such as those described on pages 12-23 of our Form 10-K filed on February 28, 2025 and other subsequent filin ...

Core Viewpoint - The current market volatility presents attractive entry opportunities for retail investors in fundamentally strong companies despite concerns over U.S.-China trade relations and economic uncertainties [1][2]. Group 1: Broadcom - Broadcom's stock has declined nearly 22% from its December 2024 high, primarily due to trade war fears, yet it remains a strong buy due to its robust AI strategy and financial health [3][7]. - The company focuses on custom XPUs for hyperscaler clients, which enhances performance and energy efficiency, with an estimated addressable market of $60 billion to $90 billion by 2027 [4][5]. - Broadcom reported a 25% year-over-year revenue increase and a 44% surge in operating income in the recent quarter, trading at a forward P/E of 29.4, significantly lower than its five-year average of 70.5 [7]. Group 2: Shopify - Shopify's stock is down nearly 25% from its February 2025 high, but it has achieved a 31% year-over-year revenue growth and a 17% operating margin, with an annual gross merchandise value of $300 billion [8][11]. - The company provides a comprehensive tech-powered omnichannel setup for merchants and is expanding its reach to larger global brands, with significant growth potential in international markets [9][10]. - Despite a forward P/E ratio of 66.2, above its five-year average of 39, the valuation is justified by its diversified business model and expected revenue growth of 25.3% year-over-year to $2.33 billion [11]. Group 3: Vertex Pharmaceuticals - Vertex Pharmaceuticals' shares have increased by nearly 23.9% in 2025, with strong growth potential driven by its dominance in the cystic fibrosis market and robust revenue visibility from its key drug, Trikafta/Kaftrio [12][13]. - The company is also expanding into blood disorders and pain management, with new treatments like Journavx and Casgevy showing promise in large patient markets [14]. - Vertex has solid financials, with $11.2 billion in cash and minimal debt, and a forward P/E of 24.2, indicating it is a worthwhile investment [15]. Group 4: Intuitive Surgical - Intuitive Surgical's shares have remained flat in 2025, but the company has a strong global presence with over 10,000 da Vinci systems installed, positioning it for future growth despite trade war challenges [16]. - The company reported an 18.5% year-over-year procedure growth and a 19% revenue increase in the first quarter of 2025, with its latest da Vinci 5 system gaining traction [17]. - Intuitive Surgical is developing advanced features for its systems and computational technologies that provide valuable insights for surgeons, which are expected to differentiate the company in the long run [18][19]. - Although the forward P/E of 56.6 may seem high, it reflects the company's market dominance and growth prospects, making it a smart investment choice [20].

Core Insights - Apple Inc. reported strong second-quarter fiscal 2025 results, exceeding revenue and earnings estimates, but shares fell 4% in after-market trading due to tariff uncertainties [1][9]. Financial Performance - Earnings per share reached $1.65, surpassing the Zacks Consensus Estimate of $1.61, marking a 7.8% increase year-over-year [3]. - Revenues increased by 5% year-over-year to $95.4 billion, exceeding the estimated $94.3 billion [3]. Product Sales - iPhone sales grew by 1.9% to $46.8 billion, driven by demand for the more affordable iPhone 16E [4]. - Services revenue, including iTunes, Apple Music, iCloud, Apple Pay, and Apple Care, rose 11.6% year-over-year to an all-time high of $26.7 billion [4]. - Mac and iPad sales increased by 6.6% to $7.95 billion and 15.2% to $6.4 billion, respectively [4]. - However, revenues from Wearables, Home, and Accessories declined by 4.9% to $7.5 billion [4]. Future Outlook - For the ongoing fiscal third quarter, Apple expects "low to mid-single digit" sales growth [5]. - CEO Tim Cook indicated a potential $900 million headwind due to tariffs in the current quarter and noted the difficulty in predicting future performance due to U.S.-China trade policy uncertainties [5]. Strategic Moves - Apple is shifting the assembly of all iPhones for the U.S. market to India, with about 50% of iPhones for the U.S. now produced in India [6]. - The company raised its quarterly dividend by 4% to 26 cents per share and announced a new stock buyback plan totaling up to $100 billion [6]. ETFs in Focus - Several ETFs with significant allocations to Apple include iShares Global Tech ETF (18.5% allocation), Vanguard Information Technology ETF (18% allocation), and others, highlighting Apple's prominence in the tech sector [2][7][10][11][12][13].

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Steel Partners Holdings L.P. (OTCQX: SPLP, SPLPP), a diversified global holding company, has qualified to trade on the OTCQX® Best Market. Steel Partners Holdings LP previously traded on the New York Stock Exchange. Steel Partners Holdings L.P.’s common and series A preferred units begin trading today on OTCQX under the symbols “ ...

Financial Data and Key Metrics Changes - The company generated $422 million in revenue for Q1 2025, with adjusted gross profit of $136 million and adjusted EBITDA of $73 million [16] - Average utilization of the rental fleet was just under 78%, up from 73% in Q1 2024, indicating improved operational efficiency [16][17] - The total OEC (Original Equipment Cost) in the rental fleet reached $1.55 billion, marking a $95 million increase year-over-year [18] Business Line Data and Key Metrics Changes - The ERS (Equipment Rental Services) segment reported $154 million in revenue, a 13% increase from $136 million in Q1 2024, with both rental revenue and rental asset sales showing significant year-over-year growth [17][18] - The PES (Product Equipment Sales) segment saw equipment sales of $232 million, slightly down from the previous year, but with a backlog increase of $51 million or 14% [19][20] - The APS (Aftermarket Parts and Services) segment maintained revenue at $35 million, flat compared to Q1 2024, with a gross profit margin of 22% [21] Market Data and Key Metrics Changes - The company noted strong demand in core T&D (Transmission and Distribution) markets, driven by increased electricity demand and maintenance spending [6][7] - Average OEC on rent for Q1 was over $1.2 billion, reflecting a 13% year-over-year increase [7][16] - The backlog in the PES segment ended at just over $420 million, consistent with historical averages [20] Company Strategy and Development Direction - The company plans to continue investing in its rental fleet to meet current and projected demand, with a focus on maintaining strong relationships with suppliers [9][21] - Management expressed confidence in achieving growth targets for 2025, reaffirming revenue guidance of $1.97 billion to $2.06 billion and adjusted EBITDA guidance of $370 million to $390 million [23][24] - The company is monitoring U.S. tariff policies closely and has implemented strategies to mitigate potential impacts on operations [11][12] Management's Comments on Operating Environment and Future Outlook - Management remains cautiously optimistic about achieving growth targets despite economic uncertainties related to tariff policies [7][14] - The company highlighted the resilience of its end markets and the importance of long-term relationships with suppliers and customers [14] - Management expects to see continued strong demand in the second half of the year, particularly in the ERS and TES segments [29] Other Important Information - Borrowings under the ABL (Asset-Based Lending) at the end of Q1 were $655 million, with a net leverage of 4.8 times [22] - The company aims to reduce net leverage to below three times by the end of fiscal 2026 [23] Q&A Session Summary Question: What gives you conviction in the acceleration in revenue growth? - Management highlighted strong demand in the ERS segment, with 13% revenue growth in Q1 and a robust backlog, indicating positive trends for the remainder of the year [26][29] Question: Does the IJ pause by the Trump administration create questions for customers? - Management noted that they are not seeing delays in projects from customers and emphasized the flexibility of their rental model [30] Question: Can you provide more color on agreements with vendors to mitigate tariff exposure? - Management discussed strong relationships with chassis suppliers and proactive inventory management to mitigate tariff impacts [38] Question: How should we think about inventory reduction by year-end? - Management indicated that inventory reduction will be more second-half weighted, with continued inventory purchases in Q2 [41] Question: How quickly do orders convert to sales revenue? - Management explained that conversion times vary by product category, with some converting quickly and others taking three to six months [51] Question: What is the target leverage by year-end? - Management aims for meaningful movement in leverage, potentially getting close to or below four times if high-end cash flow targets are met [55]